178 related articles for article (PubMed ID: 18284246)
1. Synthesis, pharmacology, and cell biology of sn-2-aminooxy analogues of lysophosphatidic acid.
Gajewiak J; Tsukahara R; Fujiwara Y; Tigyi G; Prestwich GD
Org Lett; 2008 Mar; 10(6):1111-4. PubMed ID: 18284246
[TBL] [Abstract][Full Text] [Related]
2. Synthesis of migration-resistant hydroxyethoxy analogues of lysophosphatidic acid.
Qian L; Xu Y; Arai H; Aoki J; McIntyre TM; Prestwich GD
Org Lett; 2003 Nov; 5(24):4685-8. PubMed ID: 14627415
[TBL] [Abstract][Full Text] [Related]
3. Dual activity lysophosphatidic acid receptor pan-antagonist/autotaxin inhibitor reduces breast cancer cell migration in vitro and causes tumor regression in vivo.
Zhang H; Xu X; Gajewiak J; Tsukahara R; Fujiwara Y; Liu J; Fells JI; Perygin D; Parrill AL; Tigyi G; Prestwich GD
Cancer Res; 2009 Jul; 69(13):5441-9. PubMed ID: 19509223
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and biological evaluation of phosphonate derivatives as autotaxin (ATX) inhibitors.
Cui P; Tomsig JL; McCalmont WF; Lee S; Becker CJ; Lynch KR; Macdonald TL
Bioorg Med Chem Lett; 2007 Mar; 17(6):1634-40. PubMed ID: 17257836
[TBL] [Abstract][Full Text] [Related]
5. Autotaxin and lysophosphatidic acid stimulate intestinal cell motility by redistribution of the actin modifying protein villin to the developing lamellipodia.
Khurana S; Tomar A; George SP; Wang Y; Siddiqui MR; Guo H; Tigyi G; Mathew S
Exp Cell Res; 2008 Feb; 314(3):530-42. PubMed ID: 18054784
[TBL] [Abstract][Full Text] [Related]
6. Lysophosphatidic acid-3 receptor-mediated feed-forward production of lysophosphatidic acid: an initiator of nerve injury-induced neuropathic pain.
Ma L; Uchida H; Nagai J; Inoue M; Chun J; Aoki J; Ueda H
Mol Pain; 2009 Nov; 5():64. PubMed ID: 19912636
[TBL] [Abstract][Full Text] [Related]
7. Targeting melanoma growth and viability reveals dualistic functionality of the phosphonothionate analogue of carba cyclic phosphatidic acid.
Altman MK; Gopal V; Jia W; Yu S; Hall H; Mills GB; McGinnis AC; Bartlett MG; Jiang G; Madan D; Prestwich GD; Xu Y; Davies MA; Murph MM
Mol Cancer; 2010 Jun; 9():140. PubMed ID: 20529378
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and structure-activity relationships of tyrosine-based inhibitors of autotaxin (ATX).
East JE; Kennedy AJ; Tomsig JL; De Leon AR; Lynch KR; Macdonald TL
Bioorg Med Chem Lett; 2010 Dec; 20(23):7132-6. PubMed ID: 20951039
[TBL] [Abstract][Full Text] [Related]
9. Structure-activity relationships of fluorinated lysophosphatidic acid analogues.
Xu Y; Aoki J; Shimizu K; Umezu-Goto M; Hama K; Takanezawa Y; Yu S; Mills GB; Arai H; Qian L; Prestwich GD
J Med Chem; 2005 May; 48(9):3319-27. PubMed ID: 15857137
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of autotaxin production or activity blocks lysophosphatidylcholine-induced migration of human breast cancer and melanoma cells.
Gaetano CG; Samadi N; Tomsig JL; Macdonald TL; Lynch KR; Brindley DN
Mol Carcinog; 2009 Sep; 48(9):801-9. PubMed ID: 19204929
[TBL] [Abstract][Full Text] [Related]
11. Autotaxin and LPA receptors represent potential molecular targets for the radiosensitization of murine glioma through effects on tumor vasculature.
Schleicher SM; Thotala DK; Linkous AG; Hu R; Leahy KM; Yazlovitskaya EM; Hallahan DE
PLoS One; 2011; 6(7):e22182. PubMed ID: 21799791
[TBL] [Abstract][Full Text] [Related]
12. Autotaxin signaling via lysophosphatidic acid receptors contributes to vascular endothelial growth factor-induced endothelial cell migration.
Ptaszynska MM; Pendrak ML; Stracke ML; Roberts DD
Mol Cancer Res; 2010 Mar; 8(3):309-21. PubMed ID: 20197381
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic potential of autotaxin/lysophospholipase d inhibitors.
Federico L; Pamuklar Z; Smyth SS; Morris AJ
Curr Drug Targets; 2008 Aug; 9(8):698-708. PubMed ID: 18691016
[TBL] [Abstract][Full Text] [Related]
14. ATX-LPA receptor axis in inflammation and cancer.
Liu S; Murph M; Panupinthu N; Mills GB
Cell Cycle; 2009 Nov; 8(22):3695-701. PubMed ID: 19855166
[TBL] [Abstract][Full Text] [Related]
15. Benzyl and naphthalene methylphosphonic acid inhibitors of autotaxin with anti-invasive and anti-metastatic activity.
Gupte R; Patil R; Liu J; Wang Y; Lee SC; Fujiwara Y; Fells J; Bolen AL; Emmons-Thompson K; Yates CR; Siddam A; Panupinthu N; Pham TC; Baker DL; Parrill AL; Mills GB; Tigyi G; Miller DD
ChemMedChem; 2011 May; 6(5):922-35. PubMed ID: 21465666
[TBL] [Abstract][Full Text] [Related]
16. The chemical synthesis of metabolically stabilized 2-OMe-LPA analogues and preliminary studies of their inhibitory activity toward autotaxin.
Gendaszewska-Darmach E; Laska E; Rytczak P; Okruszek A
Bioorg Med Chem Lett; 2012 Apr; 22(8):2698-700. PubMed ID: 22460025
[TBL] [Abstract][Full Text] [Related]
17. Evaluating dual activity LPA receptor pan-antagonist/autotaxin inhibitors as anti-cancer agents in vivo using engineered human tumors.
Xu X; Yang G; Zhang H; Prestwich GD
Prostaglandins Other Lipid Mediat; 2009 Sep; 89(3-4):140-6. PubMed ID: 19682598
[TBL] [Abstract][Full Text] [Related]
18. Identification of small-molecule inhibitors of autotaxin that inhibit melanoma cell migration and invasion.
Saunders LP; Ouellette A; Bandle R; Chang WC; Zhou H; Misra RN; De La Cruz EM; Braddock DT
Mol Cancer Ther; 2008 Oct; 7(10):3352-62. PubMed ID: 18852138
[TBL] [Abstract][Full Text] [Related]
19. Lysophosphatidic acids, cyclic phosphatidic acids and autotaxin as promising targets in therapies of cancer and other diseases.
Gendaszewska-Darmach E
Acta Biochim Pol; 2008; 55(2):227-40. PubMed ID: 18560605
[TBL] [Abstract][Full Text] [Related]
20. Gene expression profiles of lysophosphatidic acid-related molecules in the prostate: relevance to prostate cancer and benign hyperplasia.
Zeng Y; Kakehi Y; Nouh MA; Tsunemori H; Sugimoto M; Wu XX
Prostate; 2009 Feb; 69(3):283-92. PubMed ID: 19025891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
